Literature DB >> 11044911

Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience.

L Reeves1, P Smucker, K Cornetta.   

Abstract

During the production of clinical-grade retroviral vector supernatant, we noted significant differences in the lactate production and glucose consumption of various producer cell lines submitted to the National Gene Vector Laboratory (NGVL). Since differences in growth characteristics could be important in determining the optimal culture conditions for maximizing titer, we studied the growth characteristics of three commonly used packaging cell lines: PA317, PG13 and GP+envAM12. A transformed phenotype, assessed by the ability to form colonies in semisolid media, was evident in all three packaging cell lines tested. In confluent cultures, the rates of glucose consumption and lactate production (per cell per hour) were similar for the three lines tested, but the growth rate and culture density varied. PA317 and PG13 continued to expand after reaching confluence, resulting in higher cell densities and subsequent rapid depletion of glucose within the 24-hr observation period. When the cell lines were evaluated for titer optimization, the slower growing packaging cell line GP+envAM12 generally provided the highest titer after 8 hr of culture in confluent roller bottles, while most vectors introduced into PA317 and PG13 cells yielded optimal titers after 24 hr of culture. We also found that the improved titers obtained by culturing cells at 32 degrees C previously reported for PA317 cells do not apply to other packaging cell lines. In particular, PG13 rapidly lost titer when grown at the lower temperature. Our findings suggest that optimization of titer requires careful consideration of the culture conditions, which should be individualized for the vector producer cell line.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044911     DOI: 10.1089/104303400750001408

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

1.  Tissue-type plasminogen activator gene targets thrombolysis in atriums.

Authors:  Yongsheng Gong; Fajiu Wang; Xia Li; Zhixin Gao; Kailun Zhang; Chen Fan; Xingen Liu
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

2.  Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.

Authors:  Steven A Feldman; Stephanie L Goff; Hui Xu; Mary A Black; James N Kochenderfer; Laura A Johnson; James C Yang; Qiong Wang; Maria R Parkhurst; Scott Cross; Richard A Morgan; Kenneth Cornetta; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2010-12-12       Impact factor: 5.695

3.  Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion.

Authors:  Stephanie L Goff; Laura A Johnson; Mary A Black; Hui Xu; Zhili Zheng; Cyrille J Cohen; Richard A Morgan; Steven A Rosenberg; Steven A Feldman
Journal:  Cancer Immunol Immunother       Date:  2010-07-14       Impact factor: 6.968

4.  Genetic modification of human hematopoietic cells: preclinical optimization of oncoretroviral-mediated gene transfer for clinical trials.

Authors:  Tulin Budak-Alpdogan; Isabelle Rivière
Journal:  Methods Mol Biol       Date:  2009

5.  Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection.

Authors:  J C M van der Loo; W P Swaney; E Grassman; A Terwilliger; T Higashimoto; A Schambach; C Baum; A J Thrasher; D A Williams; D L Nordling; L Reeves; P Malik
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

6.  Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.

Authors:  Xiuyan Wang; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Shirley Bartido; Gregory Hermetet; Michel Sadelain; Isabelle Rivière
Journal:  J Immunother       Date:  2015-04       Impact factor: 4.456

Review 7.  Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy.

Authors:  Christopher S Hackett; Aron M Geurts; Perry B Hackett
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.